The administration of primary prophylaxis from the first cycle, independently of the patients and chemotherapy characteristics, and of the type of G-CSF used, protected against severe neutropenia and febrile neutropenia development and was associated to higher chemotherapy dose intensity and response rate. Here, CSF3 is linked to neutropenia.